Local view for "https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/553"

Predicate	Value (sorted: default)
rdfs:label	"evidence_1757"
rdf:type	?:Evidence ?:Item
?:Evidence_enzyme_system	""
?:Evidence_type	?:Non_traceable_Drug_Label_Statement
?:content	"7.18 CYP3A4 and -2C19 Inhibitors In vitro studies indicated that CYP3A4 and -2C19 are the primary enzymes involved in the metabolism of escitalopram. However, coadministration of escitalopram (20 mg) and ritonavir (600 mg), a potent inhibitor of CYP3A4, did not significantly affect the pharmacokinetics of escitalopram. Because escitalopram is metabolized by multiple enzyme systems, inhibition of a single enzyme may not appreciably decrease escitalopram clearance."
dc:creator	"boycer"
dc:date	"05/15/2009 10:09:13"
rdfs:seeAlso	?:13bb8267-1cab-43e5-acae-55a4d957630a

All properties reside in the graph file:///home/swish/src/ClioPatria/guidelines/dikb.ttl

The resource appears as object in one triple:

{ escitalopram_substrate_of_cyp2c19, <http://purl.org/swan/1.2/swan-commons#citesAsSupportingEvidence>, evidence_1757 }

Context graph